Methylene Blue for the Prevention of Hypotension During Hemodialysis
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Hypotension is a common complication of intermittent renal replacement therapy. Methylene
blue, an inhibitor of nitric oxide synthesis, has been suggested to improve hemodynamics
during renal replacement therapy in ambulatory patients, but evidence is lacking for
critically ill patients.
This trial will assess whether methylene blue can improve hemodynamics and blood pressure for
patients with shock requiring renal replacement therapy.